Novartis (NVS) Gets Positive CHMP Opinion for Scemblix in CML
Novartis AG announced a positive CHMP opinion recommending marketing authorization for Scemblix (asciminib) for Ph+ CML-CP treatment in adults previously treated with two or more TKIs. The EC will review the opinion, with a decision expected soon. Scemblix, if approved, offers a new CML treatment option targeting the ABL myristoyl pocket. Additionally, the EC approved Cosentyx for new juvenile arthritis indications, based on phase III study data.
Reference News
Novartis AG announced a positive CHMP opinion recommending marketing authorization for Scemblix (asciminib) for Ph+ CML-CP treatment in adults previously treated with two or more TKIs. The EC will review the opinion, with a decision expected soon. Scemblix, if approved, offers a new CML treatment option targeting the ABL myristoyl pocket. Additionally, the EC approved Cosentyx for new juvenile arthritis indications, based on phase III study data.